BioMed Realty, a Blackstone portfolio company, said Wednesday it had executed a lease amendment with Xaira Therapeutics, a leading AI-driven drug discovery company. Xaira Therapeutics is expanding its headquarters from its current 56,233-square-foot space at BioMed Realty’s Gateway of Pacific III campus, located at 700 Gateway Blvd. in South San Francisco, to a total of 73,075 square feet at the same location. 

The expansion reflects growing demand for Class A life science facilities in the Bay Area and supports Xaira’s rapid growth as a leader in AI-driven drug discovery, according to BioMed. The space will serve as a foundation for advancing Xaira’s machine-learning research and therapeutic product development, reinforcing the Bay Area’s status as a global hub for biotech and technology innovation. 

“Xaira’s new facility at BioMed Realty’s Gateway of Pacific III campus creates a collaborative and inviting space to focus on critical work that has the potential to reshape the drug development landscape through the use of AI,” said Uplaksh Kumar of Xaira.